However, as these tumors are negative for the ER, PR, and HER2 receptor, women with TNBCs were not responsive to targeted treatments (endocrine treatment or anti‐HER2 treatment) and prognostic factors predicting risk of cancer recurrence and distant metastasis in TNBC are lacking (Denkert et al., 2016; Jiang et al., 2016). This evidence concerns the gene ERBB2 and cancer.